Inna Starskaia Successfully Defends PhD Thesis on Early Immune Response in Type 1 Diabetes
Inna Starskaia from Riitta Lahesmaa lab succesfully defended her PhD thesis “Early immune response in children developing type 1 diabetes” on Friday the 15th of May. Her opponent was Professor Katri Lindfors from Tampere University.
Summary of the Dissertation:
Type 1 diabetes is a multifactorial autoimmune disorder. The pathogenesis of the disease is determined by the interplay of genetic and environmental factors, resulting in an aberrant immune response that leads to the destruction of insulin-secreting pancreatic beta cells. The appearance of islet-targeting autoantibodies, so called seroconversion, is currently the earliest biomarker for predicting the progression of type 1 diabetes before the clinical onset. One of the aims of this dissertation was to study early changes in immune responses that precede seroconversion in children who later progress to overt type 1 diabetes. In the first study we discovered numerous cell type-specific differential DNA methylation changes in circulating immune cells from children who later progressed to beta cell autoimmunity at the early stage of disease development, even prior to seroconversion. Another critical question addressed in this dissertation was the heterogeneity observed in the rate of disease progression to clinical disease as well as the post-onset beta cell decline. Recent studies reported on the existence of different disease pathways, or endotypes of type 1 diabetes behind one clinical phenotype. The second study revealed that the immune cell composition of peripheral blood mononuclear cells varied among children who later developed type 1 diabetes, when we compared children who had IAA, GADA or two autoantibodies detected as their first-appearing antibodies, supporting heterogeneity in the pathogenesis of the disease. Finally, in the third study we found that gene expression changes during the first year after clinical type 1 diabetes onset can predict the rate of disease progression. The predictive model allowed us to divide patients into rapid and slow progressors and was validated in an independent dataset of newly diagnosed type 1 diabetes patients. In conclusion, this dissertation presents findings on immune changes at the very early stage of type 1 diabetes development and support previous observations on heterogeneity of the disease.
Download the dissertation at UTUPub: https://urn.fi/URN:ISBN:978-952-02-0117-3
Recent Posts
- 35th BioCity Symposium is arranged 27–28 August 2026. Registration is now open!This year, BioCity Symposium is arranged on-site in Mauno Koivisto Centre, BioCity in 27–28 August Read moreApril 14, 2026
- Turku Protein Core Opens Two New PositionsTurku Protein Core (TuProtCore) is seeking to fill two roles: a Project Specialist in Service Read moreApril 7, 2026
- The Jane and Aatos Erkko Foundation has granted nearly €1 million to support research led by Professor Jukka Westermarck993 000 € was granted to a research project led by our Group Leader Professor Jukka Read moreApril 2, 2026
- Cecilia Sahlgren’s group discovers a new mechanism driving breast cancer progressionOur affiliated research group led by Professor Cecilia Sahlgren at Åbo Akademi University and the InFLAMES Research Read moreMarch 25, 2026
- BioCity Turku asks for proposals for Elias Tillandz publication prize winner during March 2026In the context of the 35th BioCity Symposium “Vision, Expanded” (27-28 August 2026) the twenty-second Read moreMarch 3, 2026
- Rector Widen Visited Our Centre Åbo Akademi University Rector, Gunilla Widén, visited our Centre on Wednesday, February 25th, to learn Read moreFebruary 27, 2026